The 2nd Liquid Biopsy Surveillance & Early Detection Summit returned as the industry’s only meeting showcasing biopharma-led case studies and assay developer technical progress in scaling sensitive assays that enable earlier detection and utilizing ctDNA as a surrogate biomarker to improve surveillance for a paradigm shift towards achieving personalized treatment options.

Attendees were able to stay connected and ahead of the curve with unmatched industry insights across key challenges: Sensitivity, Standardizations, Reimbursement, Clinical Utility, Multi-Cancer Early Detection, Clinical Validity, Longitudinal Monitoring

Uniting pharma, biotechs, academics, and diagnostics, this meeting was a unique opportunity to learn about the latest advancements in liquid biopsy detection and early surveillance in oncology, neurology, and rare diseases, and how they can be implemented into clinical trials and in healthy populations.